Venetoclax (Venclexta) plus fulvestrant (Faslodex) did not lead to better outcomes compared to fulvestrant alone in patients who had locally advanced or metastatic estrogen receptor (ER)-positive, HER2-negative breast cancer that was previously treated with a CDK4/6 inhibitor, according to findings from the phase 2 VERONICA trial (NCT03584009), which was presented during the 2021 ASCO Annual Meeting.
At a median follow-up of 9.9 months, the clinical benefit rate (CBR)was 11.8% (95% CI, 4.44%-23.87%) with venetoclax/fulvestrant vs 13.7% (95% CI, 5.7%-26.26%) with fulvestrant alone, translating to a risk difference of -1.96%(95% CI, -16.86%-12.94%).
The primary analysisof VERONICA revealed a largely endocrine-refractory population of patients. Venetoclax added to fulvestrant did not improve CBR orprogression-free survival [PFS], [nor did]overall survival [OS]favor [the combination],lead study author Geoffrey J. Lindeman, MD,joint head of the, Stem Cells and Cancer Division at The Walter and Eliza Hall Institute of Medical Research,saidin a virtual presentation of the data.
Despite the use of the combination of aCDK4/6 inhibitorandchemotherapy, whichhas become the standard frontline therapy for patients withmetastaticER-positive, HER2-negative breast cancer, disease progressionis inevitable.
BCL-2 is a pro-survival protein that is overexpressed in the majority of primary and relapsed ER-positive breast cancers.The BCL-2 inhibitor venetoclaxhas shown promising activity in patients withendocrine-nave, ER-positive, BCL-2positive metastatic breast cancer.
To that end, investigators evaluated the activity of adding the BCL-2 inhibitor to fulvestrant in patients withprogressive ER-positive, HER2-negative disease.
Eligibility criteria stipulated that females,18 years of age or older,had to have locally advanced or metastatic ER-positive, HER2-negativebreast cancer, received 2 or fewer lines of therapy in the locally advanced or metastatic setting without chemotherapy, received a CDK4/6 inhibitorat least 8 weeks before enrollment, and have measurable disease.
Patients were randomized 1:1 to 800 mg of oral, dailyvenetoclax (n = 51) plus 500 mg of intramuscular fulvestrant on day 1 and 15 of cycle 1 and day 1 ofeach 28-day cycle thereafteror fulvestrant alone (n = 52). Treatment was continued until disease progression, unacceptable toxicity, withdrawal of consent, death, or predefined study end.
CBR,defined as thetotal complete response(CR), partial response(PR), and stable disease rate after at least 24 weeks, served as the primary end point of the study. Secondary end pointsincludedPFS, OS, objective response rate (ORR)defined as the total CR and PR rateand duration of response (DOR).
Additional end points included safety and tolerability, biomarker analysis, pharmacokinetics, and patient-reported outcomes.
The primary analysis took place on August 5, 2020, and the updated analysis took place in April 2021.
Regarding baseline demographics, the median age was 58 years in thevenetoclax arm vs 59.5 years in the fulvestrant-alone arm.Approximately half of all patients had an ECOG performance status of 0 in both arms,at 54.9% and 59.6%, respectively. Moreover, in both arms, the majority of patients were White(78.4% vs 88.5%, respectively), had ductalhistology(78.4% vs 65.4%, respectively), at least 1 visceral metastatic lesion(92.2% vs 82.7%, respectively), and 1 prior line of endocrine therapy in the metastatic setting(80.4% vs 82.7%, respectively).
All patients had received prior endocrine therapy in the venetoclax and fulvestrant-alone arms, whereas approximately half had receivedadjuvant chemotherapy (58.8% vs 51.9%, respectively), and less than a quarter had received prior neoadjuvant chemotherapy (23.5% vs 13.5%, respectively).
The median duration of exposure to prior treatment with a CDK4/6 inhibitorin the metastatic settingwas 15 months in the venetoclax arm vs 16.5 months in the fulvestrant-alone arm,with palbociclib (Ibrance; 56.9% vs 75%, respectively) and ribociclib (Kisqali; 43.1% vs 25%, respectively).
Regarding BCL-2 status, more patients had high expressionin the venetoclax and fulvestrant-alone arms (64.7% vs 65.4%, respectively) thanlow expression (35.3% vs 34.6%, respectively).
Biomarker statusin the venetoclax and fulvestrant-alone arms, respectively,indicated the presence ofmutations in the PIK3CA (39.6% vs 30.4%),ESR1 (43.8% vs 41.3%),TP53 (47.9% vs 34.8%), andRB1 (18.8% vs 8.7%)genes.
Additional results demonstrated that the ORR was3.9% in the venetoclax arm vs 5.9% in the fulvestrant-alone arm and consisted all of PRs.
The median PFS was 2.69 months (95% CI, 1.94-3.71) in the venetoclax arm vs 1.94 months(95% CI, 1.84-3.55)in the fulvestrant-alone arm (HR, 0.94; 95% CI, 0.61-1.45;P= .7853).The 6-month PFS rates were 12.3% vs 18.8%, respectively.
The OS data were not mature at the time of the primary analysis but did not favor the venetoclax arm. The median OS was 16.76 months (95% CI, 10.12-not evaluable [NE]) in the venetoclax arm vs NE (95% CI, 16-NE) in the fulvestrant-alone arm (HR, 2.56; 95% CI, 1.11-5.89;P= .0218).The updated analysis showed comparable results, with a numerically lower hazard ratio of 1.85(95% CI, 1.01-3.39).
Notably, similar CBR and PFS was observed between arms,irrespective of BCL-2 expression.
However, increased CBR and PFS was reported in thePIK3CAwild-type subgroupin an exploratory analysis. Here, the CBR was20.7% in the venetoclax arm(n = 29) vs 9.7% in the fulvestrant-alone arm(n = 31).The median PFS was 3.71 months (95% CI, 1.94-4.53)vs 1.87 (95% CI, 1.74-3.55), respectively(HR, 0.66; 95% CI, 0.38-1.17;P=.1549).
Ahigher number of deaths was reported in the venetoclax arm vs the fulvestrant-alone arm primarily because of progressive disease at least 28 days after the last dose of study treatment. A similar trend was reported in the updated analysis.
The safety profile of the combination was consistent with the known safety profile of each agent alone, and no new signals were identified.
The occurrence of at least 1 adverse effect (AE) was reported in 94% of patients in the venetoclax arm vs 76.5% of patients in the fulvestrant-alone arm. Grade 3 or 4 AEs were reported in 26% vs 11.8% of patients, respectively.Serious AEs occurred in 8% vs 2% of patients, respectively.One case of urosepsis leading to death occurred in the venetoclax arm but was unrelated to the study drug.
Treatment-related AEs leading to drug withdrawal occurred in 8% of patients in the venetoclax arm vs 0% of patients in the fulvestrant-alone arm.AEs leading to dose modification or interruption occurred in 44% vs 2% of patients, respectively.
The most common grade 3 or 4 AEs in the venetoclax arm included fatigue (6%), neutropenia (12%), lymphopenia (4%), and dyspnea (4%)vsa 2% incidence of grade 3 or 4 fatigue in the fulvestrant-alone arm.
It remains unclear whether a BCL-2 inhibitor would be effective in an endocrine therapyresponsive, CDK4/6 inhibitornave setting, concluded Lindeman.
Reference
Lindeman GJ,Bowen R, Jerzak KJ,et al. Results from VERONICA: a randomized, phase II study of second-/third-linevenetoclax + fulvestrant vs. fulvestrantalone in estrogen receptor-positive, HER2-negative, locally advanced, or metastatic breast cancer.J Clin Oncol. 2021;39(suppl 15):1004.doi:10.1200/JCO.2021.39.15_suppl.1004
Follow this link:
Venetoclax Plus Fulvestrant Did Not Improve Outcomes Compared to Fulvestrant Alone in ER+/HER2- Breast Cancer - Cancer Network
- New Atlas of Rare Stem and Progenitor Cells Reveals New Cell Types - Inside Precision Medicine - March 28th, 2024
- Instructing iPS cell-derived mesenchymal stem cells to inhibit abnormal bone formation in FOP - Medical Xpress - March 28th, 2024
- GLP podcast: GE crops have lived up to the hype; Growing 'mini' organs from stem cells; How do we solve right-wing ... - Genetic Literacy Project - March 28th, 2024
- Exosomes and Stem Cells Are the Future of Anti-Aging - NewBeauty Magazine - March 28th, 2024
- Stem cells: past, present, and future - PMC - National Center for ... - March 19th, 2024
- Stem cells: a comprehensive review of origins and emerging clinical ... - March 19th, 2024
- Biology of stem cells: an overview - PMC - National Center for ... - March 19th, 2024
- What are Stem Cells? - Types, Applications and Sources - BYJU'S - March 19th, 2024
- Stem Cell - The Definitive Guide | Biology Dictionary - March 19th, 2024
- Colossal Creates Elephant Stem Cells for the First Time in Quest to Revive the Woolly Mammoth - Singularity Hub - March 19th, 2024
- Florida congresswoman sued the Pentagon over stem cells. One problem: her husband's stocks - Raw Story - January 23rd, 2024
- Can Stem Cells Improve Knee Pain or Are They A Waste of Money? - Bloomberg - January 23rd, 2024
- Stem cells used to successfully treat arthritis in gorilla at Budapest zoo - University of Sheffield News - January 23rd, 2024
- A computational model of stem cells' internal mechanism to recapitulate spatial patterning and maintain the self ... - Nature.com - January 23rd, 2024
- Advancing the generation of in-vivo chimeric lungs in mice using rat-derived stem cells - EurekAlert - January 6th, 2024
- 'I couldn't just give up on my dad' | Round Rock son donates stem cells to father battling leukemia - KVUE.com - January 6th, 2024
- Closing in on the ultimate quest to regenerate insulin in pancreatic stem cells - Medical Xpress - January 6th, 2024
- Ask the doctors: Research being conducted on using stem cells to treat diabetes - The Spokesman Review - January 6th, 2024
- Regenerative Medicine and COPD: Generating Functional Lungs from Pluripotent Stem Cells - Medriva - January 6th, 2024
- What is a stem cell? YourGenome - December 2nd, 2023
- Stem cell transplant - NHS - December 27th, 2022
- Stem cells: a brief history and outlook - Science in the News - December 27th, 2022
- RUDN Physician And Russian Scientists Investigate Long-term Effects Of Treating Diabetic Ulcers With Stem Cells - India Education Diary - December 27th, 2022
- Stem Cell Basics | STEM Cell Information - National Institutes of Health - December 2nd, 2022
- Neural stem cell - Wikipedia - November 24th, 2022
- Donate Stem Cells | Bone Marrow Donation - American Cancer Society - November 24th, 2022
- Stem Cells- Definition, Properties, Types, Uses, Challenges - November 6th, 2022
- Brothers from Karnataka, Prapul and Prajwal donated their stem cells, save two blood cancer patients - APN News - November 6th, 2022
- Getting These Stem Cells Treatments: Crippled Ronnie Coleman Gives a Positive Update on His Ability to Walk - EssentiallySports - October 21st, 2022
- Cornell Prof Explains Relevance of Creating Mouse Embryos from Stem Cells - Cornell University The Cornell Daily Sun - October 13th, 2022
- Human neuron clusters transplanted into rats offer new tool to study the brain : Shots - Health News - NPR - October 13th, 2022
- The neuroprotective effects of dental pulp stem cells and erythropoietin in mice hippocampus after ischemia-reperfusion - Newswise - October 13th, 2022
- A $7 million grant to grow stem cell research - Swinburne University of Technology - October 13th, 2022
- Stem Cell Manufacturing Global Market Report 2022: Widespread Product Utilization in Effective Disease Management, Personalized Medicine, and Genome... - October 13th, 2022
- Brennand named Elizabeth Mears and House Jameson Professor of Psychiatry - Yale News - October 13th, 2022
- American Academy of Stem Cell Physicians to Offer Licensed Physicians Board Examination in Regenerative Medicine - BioSpace - October 13th, 2022
- Stem Cells - alsa.org - October 4th, 2022
- Mouse embryo models built from stem cells take shape in a dish - Nature.com - October 4th, 2022
- Growth in Cell and Gene Therapy Market - Pharmaceutical Technology Magazine - October 4th, 2022
- Therapeutic Solutions International Identifies CD103 Expressing Dendritic Cells and Exosomes Thereof as Novel Mechanism for JadiCell Mesenchymal Stem... - October 4th, 2022
- Aileron Therapeutics Announces Oral Presentation of Non-Clinical Data Demonstrating ALRN-6924 Protected Human Hair Follicles and Their Stem Cells from... - October 4th, 2022
- Research Shows Promise for Directing Later Lines of Therapy for Hodgkin Lymphoma - Targeted Oncology - October 4th, 2022
- Hereditary E200K mutation within the prion protein gene alters human iPSC derived cardiomyocyte function | Scientific Reports - Nature.com - September 25th, 2022
- How To Eat Your Way to Better Health According to a Doctor - Eat This, Not That - September 25th, 2022
- Phio Pharmaceuticals Announces Preclinical Data Demonstrating PH-762 Enhances Persistence of T cells for Tumor Cell Killing as Presented by Helmholtz... - September 25th, 2022
- Types of blood cancer: Leukemia, lymphoma, and more - Medical News Today - September 25th, 2022
- September: er-blood | News and features - University of Bristol - September 25th, 2022
- Here Is Why You Heal Slower As You Age - Health Digest - September 25th, 2022
- Global Single Cell Analysis Market is Projected to Grow at a CAGR of 15.1% By 2032: Visiongain Reports Ltd - Yahoo Finance UK - September 25th, 2022
- Findings explain exceptional auditory abilities in Williams-Beuren Syndrome - EurekAlert - September 25th, 2022
- Finding the potency in planarians | Communications Biology - Nature.com - September 16th, 2022
- Life-Saving Innovations in Cancer-Fighting Stem Cell Transplants and Pioneering Research in HIV, Autism and Cerebral Palsy to be Featured at World... - September 16th, 2022
- Treating Cancer with Oncolytic Viruses - BioPharm International - September 16th, 2022
- Israel's Profuse Technology Raises $2.5M for Technology That Lowers Cost of Cultured Meat - The Spoon - September 16th, 2022
- Stem Cells Used to Grow Mouse Embryo - BioTechniques - September 8th, 2022
- Largest Gift in UCSD History to Fund Stem Cell Research on Space Station - Times of San Diego - September 8th, 2022
- Global Induced Pluripotent Stem Cells Market (2022 to 2027) - Growth, Trends, Covid-19 Impact and Forecasts - ResearchAndMarkets.com - Business Wire - September 8th, 2022
- Health on the Frontlines: The Healing Power of Stem Cells - Dans Papers - September 8th, 2022
- Top 3 grants in regenerative medicine: July 2022 - RegMedNet - September 8th, 2022
- Childhood leukemia treatment 2022: Where we are now and what it takes - EurekAlert - September 8th, 2022
- Treatment Choices for AML Were Increasingly Influenced by Immunological Responses - Physician's Weekly - September 8th, 2022
- BioRestorative Therapies to Present at the H.C. Wainwright 24th Annual Global Investment Conference on September 14 - StreetInsider.com - September 8th, 2022
- Global Recombinant Cell Culture Supplements Market Report 2022: Increasing Need for Immunotherapies and Stem Cell and Regenerative Medicines Presents... - September 8th, 2022
- CAR-T Beyond CGTs In Development In 2022 - BioProcess Online - September 8th, 2022
- ADOCIA Announces First Cell Therapy Preclinical Proof of Concept of AdoShell Islets for the Treatment of Type 1 Diabetes - Business Wire - September 8th, 2022
- Synthetic Mouse Embryo with Brain and Beating Heart Grown from Stem Cells - Genetic Engineering & Biotechnology News - August 30th, 2022
- Utilization of Modified Induced Pluripotent Stem Cells as the Advance | OPTH - Dove Medical Press - August 30th, 2022
- Rise In Number Of CROS In Various Regions Such As Europe Is Expected To Fuel The Growth Of Induced Pluripotent Stem Cell Market At An Impressive CAGR... - August 30th, 2022
- Brush Up: Hematopoietic Stem Cells and Their Role in Development and Disease Therapy - The Scientist - August 30th, 2022
- Regenerative Properties of the Newborn Heart Offers Hope for Those With Congenital Heart Disease - The Epoch Times - August 30th, 2022
- Kanpur hospital is Indias first to perform fat-derived stem cell transplant for diabetic patients - India Today - August 30th, 2022
- Scientists Just Genetically Edited a Million Years of Evolution Into Mouse DNA - ScienceAlert - August 30th, 2022
- Canadian Blood Services Stem Cells for Life - August 22nd, 2022
- Scientists say they have created 'embryos' without sperm or eggs - Medical News Today - August 22nd, 2022
- Many stem cell lines used for research and therapies carry large number of mutations, Cambridge researchers find - Cambridge Independent - August 22nd, 2022
- Scientists hope to revive extinct mammal through stem cells and gene-editing in a first - The Mirror - August 22nd, 2022
- Stem cell therapy in capsule form - Malaya - August 22nd, 2022
- Cell Culture Technician Pluripotent Stem Cell Biology and Genome Editing job with UNIVERSITY OF SOUTHAMPTON | 305107 - Times Higher Education - August 22nd, 2022
- Long COVID-19 and other chronic respiratory conditions after viral infections may stem from an overactive immune response in the lungs - The... - August 5th, 2022
- Self-organized anteroposterior regionalization of early midbrain and hindbrain using micropatterned human embryonic stem cells - Newswise - July 27th, 2022